Indeed, targeted therapies substantially improved survival in patients with advanced or metastatic melanoma from a median of 6 months obtained with chemotherapy (Korn et al., 2008), the standard of care before the approval of the first BRAF inhibitor, to a median of 25.9–33.6 months (Robert et al., 2019; Ascierto et al., 2020). Here, BRAF is linked to metastatic melanoma.